This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thomas, W. S. Articles by del Zoppo, G. J. Search for Related Content PubMed PubMed Citation Articles by Thomas, W. S. Articles by del Zoppo, G. J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Bleeding Disorders

Stroke, Vol 24, 847-853, Copyright © 1993 by American Heart Association

ARTICLES

Tissue factor contributes to microvascular defects after focal cerebral ischemia

WS Thomas, E Mori, BR Copeland, JQ Yu, JH Morrissey and GJ del Zoppo
Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, Scripps Research Institute, La Jolla, Calif 92037.

BACKGROUND AND PURPOSE: Microvascular perfusion defects occur after occlusion and reperfusion of the middle cerebral artery in examples of focal cerebral ischemia. In addition to cellular (eg, polymorphonuclear leukocyte) contributors to the focal "no-reflow" phenomenon, activation of coagulation may also play a role. We have tested a potential role of tissue factor-mediated coagulation in the microvascular perfusion defects seen after focal cerebral ischemia-reperfusion in a baboon model of reversible middle cerebral artery occlusion with the murine anti-tissue factor monoclonal antibody TF9-6B4. Tissue factor is the principal resident procoagulant substance in cerebral tissues and has a distinct perivascular distribution. METHODS: Microvascular patency in the basal ganglia after 3-hour middle cerebral artery occlusion and 1- hour reperfusion was quantified by computerized video imaging of carbon- tracer perfused tissues. Animals were randomized to receive intravenous TF9-6B4 (10 mg/kg) 10 minutes before middle cerebral artery occlusion (n = 6) or no treatment (n = 6) in an open study. RESULTS: In the control animals, a significant decrease in patency was confirmed in microvessels less than 30 microns in diameter. Infusion of TF9-6B4 before middle cerebral artery occlusion produced a stable maximal level of circulating antibody within 10 minutes, which lasted the duration of ischemia and reperfusion. An increase in reflow in microvessels of all size classes occurred after TF9-6B4 infusion, which was significant in those 7.5 to 30 microns (P = .038) and 30 to 50 microns (P = .013) in diameter. CONCLUSIONS: These results indicate that tissue factor- mediated events may also contribute to no-reflow in noncapillary microvessels after focal cerebral ischemia.

This article has been cited by other articles:

				L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al. Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat Circulation, November 29, 2005; 112(22): 3486 - 3494. [Abstract] [Full Text] [PDF]

				R. A. Adams, M. Passino, B. D. Sachs, T. Nuriel, and K. Akassoglou Fibrin Mechanisms and Functions in Nervous System Pathology Mol. Interv., June 1, 2004; 4(3): 163 - 176. [Abstract] [Full Text] [PDF]

				P Connor and B J Hunt Cerebral haemostasis and antiphospholipid antibodies Lupus, December 1, 2003; 12(12): 929 - 934. [Abstract] [PDF]

				D. Bonderman, A. Teml, J. Jakowitsch, C. Adlbrecht, M. Gyongyosi, W. Sperker, H. Lass, W. Mosgoeller, D. H. Glogar, P. Probst, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque Blood, April 15, 2002; 99(8): 2794 - 2800. [Abstract] [Full Text] [PDF]

				J. R. Toomey, R. E. Valocik, P. F. Koster, M. A. Gabriel, M. McVey, T. K. Hart, E. H. Ohlstein, A. A. Parsons, and F. C. Barone Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke Stroke, February 1, 2002; 33(2): 578 - 585. [Abstract] [Full Text] [PDF]

				G. J. del Zoppo, K. J. Becker, and J. M. Hallenbeck Inflammation After Stroke: Is It Harmful? Arch Neurol, April 1, 2001; 58(4): 669 - 672. [Full Text] [PDF]

				J. Huang, J. Mocco, T. F. Choudhri, A. Poisik, S. J. Popilskis, R. Emerson, R. L. DelaPaz, A. G. Khandji, D. J. Pinsky, E. S. Connolly Jr, et al. A Modified Transorbital Baboon Model of Reperfused Stroke Editorial Comment Stroke, December 1, 2000; 31(12): 3054 - 3063. [Abstract] [Full Text] [PDF]

				T. Abumiya, R. Fitridge, C. Mazur, B. R. Copeland, J. A. Koziol, J. F. Tschopp, M. D. Pierschbacher, G. J. del Zoppo, and P. D. Hurn Integrin {alpha}IIb{beta}3 Inhibitor Preserves Microvascular Patency in Experimental Acute Focal Cerebral Ischemia Editorial Comment Stroke, June 1, 2000; 31(6): 1402 - 1410. [Abstract] [Full Text] [PDF]

				H. Tomimoto, I. Akiguchi, H. Wakita, A. Osaki, M. Hayashi, and Y. Yamamoto Coagulation Activation in Patients With Binswanger Disease Arch Neurol, September 1, 1999; 56(9): 1104 - 1108. [Abstract] [Full Text] [PDF]

				G. J DEL ZOPPO, R. VON KUMMER, and G. F HAMANN Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 1 - 9. [Full Text]

				N. J. Solenski, A.-L. Kwan, H. Yanamoto, J. P. Bennett, N. F. Kassell, and K. S. Lee Differential Hydroxylation of Salicylate in Core and Penumbra Regions During Focal Reversible Cerebral Ischemia Stroke, December 1, 1997; 28(12): 2545 - 2552. [Abstract] [Full Text]

				M. R. D. Bigio, H.-J. Yan, R. Buist, J. Peeling, and G. J. del Zoppo Experimental Intracerebral Hemorrhage in Rats: Magnetic Resonance Imaging and Histopathological Correlates Stroke, December 1, 1996; 27(12): 2312 - 2320. [Abstract] [Full Text]